With a continued focus on customers, BioDiscovery moves from a sales and support departmental structure to a holistic team filled with Customer Success Managers.
At the American Society of Clinical Oncology (ASCO) meeting last month, Dr. Nathan Pennell, Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic, and his colleagues presented cost analysis in a model with different types of genetics testing in metastatic non-small cell lung cancer (mNSCLC). The team showed that upfront NGS leads to significant cost savings vs. sequential single-gene testing modalities.
BioDiscovery inked a deal with Be Creative Lab (Beijing) Co. Ltd. where Be Creative will be the sole reseller and distributor of BioDiscovery products in China. Be Creative is a clinical genetic testing center in Beijing, China, providing diagnostic support for a number of hospitals. Be Creative debuted NxClinical 4.0 at the Clinical Applications Conference which focused on comprehensive application of SNP-Array, NGS and other technology platforms to enhance clinical diagnostics. The conference, hosted by Be Creative, brought together 200 clinical genetics experts.
To further enhance quality assurance, ClinGen now puts forth a list of clinical laboratories that meet minimum requirements for data sharing.
Dr. Breen of North Carolina State University has been a long time user of our Nexus Copy Number software and we were pleased to learn of his application of his latest patent: a new, non-invasive method of diagnosing bladder cancer in dogs.
WES and SNP arrays detect concordant gene-level alterations. Learn how CNV detection from whole-exome sequencing (WES) compares with SNP microarray.
Learn more about CNV analysis by reading this review of the challenges with detecting copy number variations with next-generation sequencing.